Individual Stress Vulnerability Is Predicted by Short-Term Memory and AMPA Receptor Subunit Ratio in the Hippocampus

Increased vulnerability to aversive experiences is one of the main risk factors for stress-related psychiatric disorders as major depression. However, the molecular bases of vulnerability, on the one hand, and stress resilience, on the other hand, are still not understood. Increasing clinical and preclinical evidence suggests a central involvement of the glutamatergic system in the pathogenesis of major depression. Using a mouse paradigm, modeling increased stress vulnerability and depression-like symptoms in a genetically diverse outbred strain, and we tested the hypothesis that differences in AMPA receptor function may be linked to individual variations in stress vulnerability. Vulnerable and resilient animals differed significantly in their dorsal hippocampal AMPA receptor expression and AMPA receptor binding. Treatment with an AMPA receptor potentiator during the stress exposure prevented the lasting effects of chronic social stress exposure on physiological, neuroendocrine, and behavioral parameters. In addition, spatial short-term memory, an AMPA receptor-dependent behavior, was found to be predictive of individual stress vulnerability and response to AMPA potentiator treatment. Finally, we provide evidence that genetic variations in the AMPA receptor subunit GluR1 are linked to the vulnerable phenotype. Therefore, we propose genetic variations in the AMPA receptor system to shape individual stress vulnerability. Those individual differences can be predicted by the assessment of short-term memory, thereby opening up the possibility for a specific treatment by enhancing AMPA receptor function.

[1]  B. Giros,et al.  Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. , 2010, The international journal of neuropsychopharmacology.

[2]  F. Holsboer,et al.  High susceptibility to chronic social stress is associated with a depression-like phenotype , 2010, Psychoneuroendocrinology.

[3]  P. Cowen,et al.  A Functional Magnetic Resonance Imaging Study of Verbal Working Memory in Young People at Increased Familial Risk of Depression , 2010, Biological Psychiatry.

[4]  Hong-wei Dong,et al.  Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures? , 2010, Neuron.

[5]  K. Hashimoto Emerging role of glutamate in the pathophysiology of major depressive disorder , 2009, Brain Research Reviews.

[6]  M. Banasr,et al.  Chronic treatment with AMPA receptor potentiator Org 26576 increases neuronal cell proliferation and survival in adult rodent hippocampus , 2009, Psychopharmacology.

[7]  N. Hasebe,et al.  Effects of antidepressants on GluR2 Q/R site-RNA editing in modified HeLa cell line , 2009, Neuroscience Research.

[8]  Mark A Good,et al.  Enhanced long-term and impaired short-term spatial memory in GluA1 AMPA receptor subunit knockout mice: evidence for a dual-process memory model. , 2009, Learning & memory.

[9]  H. Manji,et al.  The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology and Therapeutics of Mood Disorders , 2009, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[10]  Marian Joëls,et al.  Version unknown SOURCE ( OR PART OF THE FOLLOWING SOURCE ) : Type article Title Corticosterone alters AMPAR mobility and facilitates bidirectional synaptic plasticity , 2009 .

[11]  S. Southwick,et al.  Social support and resilience to stress across the life span: A neurobiologic framework , 2008, Current psychiatry reports.

[12]  R. Sprengel,et al.  AMPA receptor subunit 1 (GluR‐A) knockout mice model the glutamate hypothesis of depression , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  Carlos A. Zarate,et al.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders , 2008, Nature Reviews Drug Discovery.

[14]  R. McIntyre,et al.  What Are the Implications of the STAR*D Trial for Primary Care? A Review and Synthesis. , 2008, Primary care companion to the Journal of clinical psychiatry.

[15]  Guang Chen,et al.  Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors , 2008, Biological Psychiatry.

[16]  C. Zarate,et al.  The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects , 2007, Current psychiatry reports.

[17]  T. Macedo,et al.  Methamphetamine induces alterations on hippocampal NMDA and AMPA receptor subunit levels and impairs spatial working memory , 2007, Neuroscience.

[18]  P. Greengard,et al.  Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine , 2007, The European journal of neuroscience.

[19]  Chris J. McBain,et al.  The Role of the GluR2 Subunit in AMPA Receptor Function and Synaptic Plasticity , 2007, Neuron.

[20]  F. Holsboer,et al.  Persistent neuroendocrine and behavioral effects of a novel, etiologically relevant mouse paradigm for chronic social stress during adolescence , 2007, Psychoneuroendocrinology.

[21]  Steven Finkbeiner,et al.  NMDA and AMPA receptors: old channels, new tricks , 2007, Trends in Neurosciences.

[22]  A. Arai,et al.  Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. , 2007, Current drug targets.

[23]  M. O'Neill,et al.  AMPA receptor potentiators: application for depression and Parkinson's disease. , 2007, Current drug targets.

[24]  J. Witkin,et al.  AMPA receptors in the therapeutic management of depression. , 2007, CNS & neurological disorders drug targets.

[25]  Takeshi Yamada,et al.  Short communication Correlation between plasma levels of glutamate, alanine and serine with severity of depression , 2006 .

[26]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[27]  E. Chudin,et al.  A Model of Technical Variation of Microarray Signals , 2006, J. Comput. Biol..

[28]  E. Nisenbaum,et al.  LY404187: a novel positive allosteric modulator of AMPA receptors. , 2006, CNS drug reviews.

[29]  E. Nisenbaum,et al.  A role for AMPA receptors in mood disorders. , 2006, Biochemical pharmacology.

[30]  M. Popoli,et al.  Regulation of Editing and Expression of Glutamate α-Amino-Propionic-Acid (AMPA)/Kainate Receptors by Antidepressant Drugs , 2006, Biological Psychiatry.

[31]  S. Brady,et al.  Gender differences in response of hippocampus to chronic glucocorticoid stress: Role of glutamate receptors , 2006, Journal of neuroscience research.

[32]  R. W. Draft,et al.  Restoration of spatial working memory by genetic rescue of GluR-A–deficient mice , 2005, Nature Neuroscience.

[33]  N. Datson,et al.  Expression profiling in laser‐microdissected hippocampal subregions in rat brain reveals large subregion‐specific differences in expression , 2004, The European journal of neuroscience.

[34]  JianLi Wang Work stress as a risk factor for major depressive episode(s) , 2004, Psychological Medicine.

[35]  H. Manji,et al.  Modulation of Synaptic Plasticity by Antimanic Agents: The Role of AMPA Glutamate Receptor Subunit 1 Synaptic Expression , 2004, The Journal of Neuroscience.

[36]  H. Anisman,et al.  Validation of a simple, ethologically relevant paradigm for assessing anxiety in mice , 2003, Biological Psychiatry.

[37]  Olga V. Demler,et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.

[38]  M. Bergeron,et al.  Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus , 2003, Neuropharmacology.

[39]  David Bleakman,et al.  An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study , 2002, Neuropharmacology.

[40]  I. Izquierdo,et al.  Molecular Pharmacological Dissection of Short- and Long-Term Memory , 2002, Cellular and Molecular Neurobiology.

[41]  P. Skolnick,et al.  Intra- and interstrain differences in models of “behavioral despair” , 2001, Pharmacology Biochemistry and Behavior.

[42]  J. Meador-Woodruff,et al.  Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder , 2001, Brain Research Bulletin.

[43]  D. Bleakman,et al.  Pharmacological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro , 2001, Neuropharmacology.

[44]  P. Skolnick,et al.  Antidepressant-like actions of an AMPA receptor potentiator (LY392098) , 2001, Neuropharmacology.

[45]  P. Ornstein,et al.  Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro , 2001, Neuropharmacology.

[46]  D. Lodge,et al.  Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo , 2001, Neuropharmacology.

[47]  M. Oitzl,et al.  A refined method for sequential blood sampling by tail incision in rats , 2000, Laboratory animals.

[48]  D. Charney Monoamine dysfunction and the pathophysiology and treatment of depression. , 1998, The Journal of clinical psychiatry.

[49]  Michael C. Neale,et al.  Stressful life events, genetic liability, and onset of an episode of major depression in women. , 1995, The American journal of psychiatry.

[50]  J. Kleinman,et al.  Properties of [3H]AMPA Binding in Postmortem Human Brain from Psychotic Subjects and Controls: Increases in Caudate Nucleus Associated with Suicide , 1993, Experimental Neurology.

[51]  D. Choquet,et al.  [Surface mobility of postsynaptic AMPARs tunes synaptic transmission]. , 2008, Medecine sciences : M/S.

[52]  H. Kornhuber,et al.  Increased serum glutamate in depressed patients , 2004, Archiv für Psychiatrie und Nervenkrankheiten.